Drug Pricing: Trump Indicators “Most Favored Nation” Govt Order

On Could 12, 2025, President Trump signed the second drug pricing-related Govt Order (EO) of his present administration. Whereas President Trump’s first drug pricing-related EO centered on decreasing the price of prescribed drugs by persevering with and modifying the negotiations initiated by the Inflation Discount Act of 2022 and issuing directives for administrative businesses to provoke value cuts, this EO focuses on international comparative pricing.

The EO states that whereas Americans symbolize solely 5% of the worldwide inhabitants, they fund round 75% of world pharmaceutical income, thus inflicting People to underwrite the lion’s share of drug analysis and improvement for the worldwide inhabitants. The EO claims that this discrepancy is rooted in a world worth discrimination “scheme” whereby People pay upward of thrice the fee for prescription drugs when in comparison with different equally located nations. This follow is alleged to have arisen as the results of pharmaceutical firms preventing in opposition to the power of each private and non-private payors to barter for higher drug costs for American sufferers. The EO concludes that the present scheme affords overseas well being methods a “free trip” at the price of American’s “generosity.” In an effort to rebut this follow, the EO directs that People, as the most important shopper of pharmaceutical merchandise, obtain “most-favored nation” pricing for prescription drugs. Stated in a different way, below the EO, People would obtain the pharmaceutical pricing equal to the equally located nation receiving the most effective pricing.

To deal with this discrepancy, the EO makes a number of directives together with the next:

• The Division of Well being & Human Providers (HHS) shall facilitate direct-to-consumer (somewhat than insurance-based) buying packages for pharmaceutical firms to promote their product at most-favored nation pricing.
• United States Commerce Representatives and the Secretary of Commerce shall be certain that overseas nations usually are not engaged in any unreasonably discriminatory drug-pricing practices or insurance policies.
• Inside 30 days of the EO, the Secretary of HHS, Robert F. Kennedy, Jr., together with the Facilities for Medicare & Medicaid Providers shall set up “goal costs” for pharmaceutical merchandise in step with most-favored nation pricing.
• Ought to pharmaceutical firms fail to make “important progress” voluntarily bringing their costs to the most-favored nation goal worth, the Administration shall have interaction in rulemaking to implement most-favored nation costs. 

These rulemaking processes aimed toward encouraging pharmaceutical firms to adjust to providing essentially the most favored nation pricing for his or her merchandise to American shoppers consists of:

• HHS certification that importation of prescribed drugs from different nations pursuant to 804(j) of the Federal Meals, Drug, and Beauty Act (FDCA) poses no extra threat to the well being and security of shoppers in addition to a transparent pathway for importation of low-cost prescription drug options from different equally located nations.
• Secretary of Commerce pursuing enforcement of anticompetitive practices perpetuated by pharmaceutical firms.
• Secretary of Commerce motion regulating the export of medication or precursor materials for drug manufacturing.
• Commissioner of Meals and Medication revoking approval for medicine which were improperly marketed or deemed ineffective or unsafe. 
• Motion by all company heads to deal with “international freeloading and worth discrimination in opposition to American affected person.”

This isn’t the primary time the Trump administration has addressed drug pricing relative to different equally located nations. In late 2020, the primary Trump Administration proposed an Govt Order requiring Medicare Half B drug costs to align with most-favored nation pricing. This EO confronted important challenges in courtroom and was in the end dropped by the Biden Administration. 

Although this present EO has acquired important press, a number of questions stay unanswered together with how goal costs might be recognized and the allowable timeframe for pharmaceutical firms to voluntarily make “important progress.” PhRMA, a pharmaceutical {industry} foyer group, responded to the EO nearly instantly, calling it a “dangerous deal for American sufferers.” 

Foley is right here that can assist you handle the brief and long-term impacts within the wake of regulatory modifications. Now we have the sources that can assist you navigate these and different necessary authorized concerns associated to enterprise operations and industry-specific points. Please attain out to the authors, your Foley relationship accomplice, or to our Well being Care Follow Group and Well being Care & Life Sciences Sector with any questions.

The publish Drug Pricing: Trump Indicators “Most Favored Nation” Govt Order appeared first on Foley & Lardner LLP.